hACE2-Binding Antibody to Block SARS-CoV-2 Cell Entry

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current strategies are inadequate in preventing the binding of SARS-CoV2 to human angiotensin-converting enzyme 2 (hACE2) proteins, which is crucial for viral entry into human cells, leading to COVID-19 infection.

Innovation Solution

Development of an antiviral antibody that binds to hACE2, inhibiting the entry of SARS-CoV2 into cells, and is formulated into a pharmaceutical composition for prevention or treatment.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current strategies are used to prevent SARS-CoV2 binding to hACE2, then the prevention mechanism is insufficient, but the virus can still enter human cells causing infection

Engineering Contradiction:

Improveprevention effectivenessVSAvoidviral entry capability

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces an antibody as an intermediary substance that binds to the hACE2 protein, physically blocking the interaction between the viral spike protein and the hACE2 receptor. This mediator (antibody-hACE2 complex) prevents direct binding of SARS-CoV2 to the receptor, thereby blocking viral entry into human cells and establishing reliable prevention against infection

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If an antibody binding to hACE2 is developed, then viral entry is blocked effectively, but the complexity of the solution increases

Engineering Contradiction:

Improveviral entry capabilityVSAvoidsolution complexity

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The antibody exhibits self-service characteristics by autonomously binding to the hACE2 protein and maintaining a stable blocking configuration without requiring external energy input or complex control systems. The antibody-hACE2 complex forms through specific molecular recognition and remains stable under physiological conditions, providing sustained prevention of viral entry without additional complexity in maintaining the preventive state

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antibody effectively prevents SARS-CoV2 infection by blocking viral entry into cells, demonstrating antiviral efficacy through reduced infection rates.

Implementation Method 1

SARS-CoV2 binds to an angiotensin-converting enzyme 2 (hACE2) protein which is mainly present in human lung epithelial cells... The spike protein S1-receptor binding domain (RBD) present on the surface of corona virus binds to a hACE2 protein... blocking of the binding between SARS-CoV2 and hACE2 may fundamentally prevent cellular invasion of coronaviruses

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS20250270297A1Antiviral antibody against SARS-cov2 binding to ace2, and use thereof

Publication Date: 2025.08.28 DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

AI summary

The present invention relates to an antiviral antibody against SARS-CoV2 binding to ACE2 and a use thereof. The objective of the present invention is to prepare an antibody which binds to hACE2, and confirm that the antibody exhibits an antiviral effect against SARS-CoV2 by verifying that each antibody inhibits SARS-CoV2 virus entry into cells, thereby providing a composition comprising the antibody as a pharmaceutical composition for preventing or treating infection caused by SARS-CoV2.